
Quarterly report 2025-Q3
added 11-19-2025
ProPhase Labs Net Debt 2011-2026 | PRPH
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt ProPhase Labs
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.41 M | 2.25 M | -5.18 K | 492 K | -1.55 M | -3.17 M | 1.05 M | -198 K | -2.93 M | -1.64 M | -572 K | -5.54 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.25 M | -6.41 M | -1.52 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | ||
|
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
193 M | $ 1.1 | 2.84 % | $ 118 M | ||
|
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
-1.07 B | $ 2.64 | 1.35 % | $ 1.38 B | ||
|
Evolus
EOLS
|
94.8 M | $ 5.68 | 37.53 % | $ 366 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.59 | 6.08 % | $ 10.3 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 3.81 | -16.81 % | $ 53.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | ||
|
Harrow Health
HROW
|
178 M | $ 40.02 | 3.65 % | $ 1.47 B | ||
|
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
285 M | $ 3.65 | 4.89 % | $ 86.3 M | ||
|
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | ||
|
Emergent BioSolutions
EBS
|
338 M | $ 8.95 | 0.39 % | $ 458 M | ||
|
Assertio Holdings
ASRT
|
-34 M | $ 12.19 | 2.48 % | $ 866 M | ||
|
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
21.1 B | $ 5.67 | -0.87 % | $ 2.07 B | ||
|
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | ||
|
Organogenesis Holdings
ORGO
|
-131 M | $ 2.87 | 0.01 % | $ 378 M | ||
|
OrganiGram Holdings
OGI
|
90.7 M | $ 1.4 | 2.19 % | $ 402 M | ||
|
Rockwell Medical
RMTI
|
691 K | $ 0.91 | 1.03 % | $ 21.2 M | ||
|
Perrigo Company plc
PRGO
|
3.1 B | $ 11.71 | 2.81 % | $ 1.62 B | ||
|
Sundial Growers
SNDL
|
-28.4 M | $ 1.55 | 1.21 % | $ 3.37 M | ||
|
TherapeuticsMD
TXMD
|
3.68 M | $ 2.25 | 1.35 % | $ 23.5 M | ||
|
Veru
VERU
|
-20.9 M | $ 2.53 | 0.4 % | $ 341 M | ||
|
Viatris
VTRS
|
16.8 B | $ 14.74 | -1.04 % | $ 17.7 B | ||
|
Pacira BioSciences
PCRX
|
317 M | $ 22.92 | 3.69 % | $ 1.06 B | ||
|
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
-2.5 M | $ 4.79 | 2.57 % | $ 144 M | ||
|
cbdMD
YCBD
|
-521 K | $ 0.75 | -2.76 % | $ 3.23 M | ||
|
SCYNEXIS
SCYX
|
-31.1 M | $ 0.76 | 1.22 % | $ 36.4 M | ||
|
Solid Biosciences
SLDB
|
-70.9 M | $ 6.14 | 3.02 % | $ 251 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 2.74 | -0.36 % | $ 3.4 M | ||
|
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
14.4 M | $ 7.33 | -0.48 % | $ 4.53 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M |